KIF18A-IN-6

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity In Vitro KIF18A-IN-6 (Compound 134; 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCC-15, JIMT-1 and NIH-OVCAR3 Concentration: Incubation Time: 7 days Result: Inhibited cell viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively. In Vivo KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) inhibits HCC15 and OVCAR3 tumor growth in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID Beige mice, HCC15 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice a day for 1 month Result: Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively. Animal Model: Balb/C nude mice, OVCAR3 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice or once a day for 1 month Result: Completely inhibited tumor growth (over 100%) over 30 mg/kg. Form:Solid IC50& Target:IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet